Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEF9JW)

• Drug Name: IM0-8400 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Discontinued in Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMEF9JW

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 9 (TLR9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[3]
SD-101	DMAMTGI	Hepatitis C virus infection	1E51.1	Phase 3	[4]
MGN-1703	DMCJRL1	Colorectal cancer	2B91.Z	Phase 3	[5]
IMO-2125	DM735FA	Melanoma	2C30	Phase 3	[6]
Tilsotolimod	DMGYK2N	Melanoma	2C30	Phase 3	[7]
MIS-416	DM7K4YR	Autoimmune diabetes	5A10	Phase 2	[8]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[9]
BL-7040	DMSBPJI	Inflammatory bowel disease	DD72	Phase 2	[10]
CYT003	DM4LJH8	Asthma	CA23	Phase 2	[11]
CpG-10101	DM6MUCX	Hepatitis C virus infection	1E51.1	Phase 2	[12]

Drug(s) Targeting Toll-like receptor 7 (TLR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[13]
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[14]
ANA773	DMSC8YW	Hepatitis C virus infection	1E51.1	Phase 2a	[15]
GS-9620	DMG5C8D	Hepatitis B virus infection	1E51.0	Phase 2	[16]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[9]
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[17]
LOXORIBINE	DMIV9ZE	Immune System disease	4A01-4B41	Phase 2	[18]
GSK2245035	DMBWPZJ	Asthma	CA23	Phase 2	[19]
AZD-8848	DM0M7QW	Allergic rhinitis	CA08.0	Phase 2	[20]
Isatoribine	DMHOJ8W	Hepatitis C virus infection	1E51.1	Phase 2	[21]

Drug(s) Targeting Toll-like receptor 8 (TLR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[17]
Selgantolimod	DMST4OR	Hepatitis B	1E51	Phase 2	[22]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[23]
NKTR-262	DMYR8LF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[24]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[25]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[26]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
SBT6050	DMHBD3T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[28]
VTX-1463	DM4ZIRK	Allergic rhinitis	CA08.0	Phase 1	[29]
DN1508052	DM0JT9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Antagonist	[2]
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Antagonist	[2]
Toll-like receptor 9 (TLR9)	TTSHG0T	TLR9_HUMAN	Antagonist	[2]

References

• [1] Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
• [2] Clinical pipeline report, company report or official report of Idera Pharmaceuticals.
• [3] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [4] Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829.
• [5] Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24.
• [6] Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
• [7] Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020.
• [8] DOI: 10.1371/journal.pone.0087712
• [9] Company report (Iderapharma)
• [10] Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14.
• [11] CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8.
• [12] Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51.
• [13] Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
• [14] TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
• [15] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [16] Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
• [17] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [18] The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
• [19] Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
• [20] Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
• [21] Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
• [22] Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [24] Clinical pipeline report, company report or official report of Nektar Therapeutics.
• [25] Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
• [26] Clinical pipeline report, company report or official report of CureVac.
• [27] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [28] Clinical pipeline report, company report or official report of Silverback Therapeutics.
• [29] VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
• [30] Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.